The implantable cardioverter defibrillator (ICD) represented a breakthrough in the prevention of sudden cardiac death. In addition to its use in secondary prevention, the indication of ICD therapy in primary prevention is also being intensively researched. A study published last year evaluated the relevance of ICD implantation in the acute phase of acute myocarditis and a registry study investigated the benefits of a wearable cardioverter defibrillator (WCD) for the prevention of sudden cardiac death in post-infarction patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Collagenoses
Scleroderma – Current recommendations for diagnosis and therapy 2025
- Multiple sclerosis
Avoiding the nocebo trap with natalizumab biosimilars
- COPD and comorbidities
Exacerbation frequency is associated with cardiopulmonary disease burden
- Multiple myeloma
DREAMM-8: Key study in the development of BCMA therapy up to DREAMM-14
- Catheter ablation for atrial fibrillation 2025
Pulsed field versus radio frequency – where do we stand?
- Atopic dermatitis
From skin barrier disorder to atopic march?
- From the late residual valve to independent therapy
Tricuspid interventions 2025
- Brain health